We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.23B
1-Year Est. Return
81.32%
This Fund
S&P 500
This Quarter
Est. Return
+5.32%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.6B
AUM Growth
-$496M
(-24%)
Cap. Flow
-$440M
Cap. Flow
% of AUM
-27.44%
Top 10 Holdings %
Top 10 Hldgs %
54.93%
Holding
55
New
3
Increased
15
Reduced
6
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Disc Medicine
IRON
|
+$117M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$17.4M |
| 3 |
BLU
BELLUS Health Inc.
BLU
|
+$15.8M |
| 4 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
+$15.2M |
| 5 |
Rallybio
RLYB
|
+$12.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Total Stock Market ETF
VTI
|
+$501M |
| 2 |
ACLX
Arcellx
ACLX
|
+$39.2M |
| 3 |
Brookfield
BN
|
+$20M |
| 4 |
Milestone Pharmaceuticals
MIST
|
+$18.4M |
| 5 |
Boston Scientific
BSX
|
+$17.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 69.58% |
| 2 | Technology | 18.99% |
| 3 | Financials | 4.49% |
| 4 | Communication Services | 4.18% |
| 5 | Consumer Discretionary | 2.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Stryker
SYK
$135B
| $195M | 12.17% |
796,941
| – | – |
|
2
ASML
ASML
$596B
| $124M | 7.74% |
226,770
| – | – |
|
3
Steris
STE
$22.9B
| $86.4M | 5.39% |
467,687
| – | – |
|
4
Salesforce
CRM
$154B
| $76.7M | 4.79% |
578,500
| – | – |
|
|
CTLT
5
DELISTED
CATALENT, INC.
CTLT
| $73.5M | 4.59% |
1,632,878
| – | – |
|
|
6
Brookfield
BN
$102B
| $71.9M | 4.49% |
3,763,245
-891,889
| -19% | -$20M |
|
7
Corcept Therapeutics
CORT
$9.98B
| $68.6M | 4.28% |
3,377,768
+50,000
| +2% | +$1.25M |
|
8
Cable One
CABO
$237M
| $67M | 4.18% |
94,103
+14,080
| +18% | +$10.5M |
|
|
9
Boston Scientific
BSX
$68.4B
| $62.6M | 3.91% |
1,353,081
-409,861
| -23% | -$17.7M |
|
10
Edgewise Therapeutics
EWTX
$4.28B
| $54.3M | 3.39% |
6,071,703
| – | – |
|
11
TSMC
TSM
$1.94T
| $52.9M | 3.31% |
710,780
| – | – |
|
12
Apple
AAPL
$4.97T
| $48M | 2.99% |
369,104
-92,275
| -20% | -$13.2M |
|
|
13
Disc Medicine
IRON
$2.81B
| $46.6M | 2.91% |
+2,340,772
| New | +$117M |
|
|
ACLX
14
DELISTED
Arcellx
ACLX
| $46M | 2.87% |
1,484,020
-1,707,858
| -54% | -$39.2M |
|
15
Alibaba
BABA
$276B
| $44.1M | 2.75% |
500,827
| – | – |
|
16
Vaxcyte
PCVX
$7.65B
| $34.8M | 2.17% |
725,000
-98,705
| -12% | -$3.87M |
|
17
BioMarin Pharmaceuticals
BMRN
$11.9B
| $32.9M | 2.05% |
317,700
+200
| +0.1% | +$18.8K |
|
18
Mirum Pharmaceuticals
MIRM
$6.56B
| $32.8M | 2.05% |
1,684,193
| – | – |
|
|
VECT
19
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $28.9M | 1.81% |
3,339,484
| – | – |
|
|
SGEN
20
DELISTED
Seagen Inc. Common Stock
SGEN
| $27M | 1.69% |
210,000
+135,000
| +180% | +$17.4M |
|
21
Alnylam Pharmaceuticals
ALNY
$38.3B
| $26.6M | 1.66% |
112,000
+12,000
| +12% | +$2.56M |
|
|
FOLD
22
DELISTED
Amicus Therapeutics
FOLD
| $25.6M | 1.6% |
2,095,900
-4,100
| -0.2% | -$46.2K |
|
|
VERV
23
DELISTED
Verve Therapeutics
VERV
| $17.6M | 1.1% |
911,111
| – | – |
|
24
Insmed
INSM
$22.4B
| $16.8M | 1.05% |
840,000
+70,000
| +9% | +$1.35M |
|
25
Rocket Pharmaceuticals
RCKT
$343M
| $16.6M | 1.04% |
850,000
+217,178
| +34% | +$4M |
|
Similar funds
HCA
GX
MP
FLII
IC
CCA
WCM
IA
Novo Holdings A/S's Q4 2022 Portfolio in Review
As of Q4 2022, Novo Holdings A/S held 55 positions worth $1.6B, down 24% from $2.1B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Novo Holdings A/S withdrew a net $440M in Q4 2022, closing 7 positions and reducing 6 holdings. Its most notable exit was Vanguard Total Stock Market ETF, an estimated $501M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 52% a quarter earlier, followed by Technology and Financials.
Against the trend, Novo Holdings A/S opened a new position in Disc Medicine worth $46.6M.
- Novo Holdings A/S's largest Q4 2022 buy was Disc Medicine: 2,340,772 shares worth $46.6M.
- Novo Holdings A/S added most to Seagen Inc. Common Stock in Q4 2022, an estimated $17.4M increase.
- Novo Holdings A/S's biggest Q4 2022 reduction was Arcellx, cutting an estimated $39.2M.
- Novo Holdings A/S fully exited Vanguard Total Stock Market ETF in Q4 2022, selling an estimated $501M.
- Novo Holdings A/S's ten largest holdings make up 55% of its $1.6B portfolio in Q4 2022.
- Novo Holdings A/S opened 3 new positions and closed 7 in Q4 2022.
- Novo Holdings A/S's portfolio value fell 24% quarter-over-quarter to $1.6B.
Based on Novo Holdings A/S's 13F filing for Q4 2022, filed 14 Feb 2023.